Stubborn stasis in the prevalence of metabolic syndrome: a case for pharmacotherapy-based innovation for cardiovascular health
- 16 September 2026
- journal article
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Estimated global prevalence of metabolic syndrome: a proportional meta-analysisEuropean Journal of Cardiovascular Nursing, 2026
- Making treatment for obesity more equitableThe Lancet, 2026
- World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in AdultsJAMA, 2026
- GLP-1 receptor agonists for obesity: eligibility across 99 countriesThe Lancet Diabetes & Endocrinology, 2026
- Tirzepatide for Obesity Treatment and Diabetes PreventionNew England Journal of Medicine, 2025
- Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialThe Lancet, 2024
- Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trialNature Medicine, 2024
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- Treating chronic diseases without tackling excess adiposity promotes multimorbidityThe Lancet Diabetes & Endocrinology, 2022
- The challenge of keeping it off, a descriptive systematic review of high‐quality, follow‐up studies of obesity treatmentsObesity Reviews, 2019